Carbamyl analogues of potent nicotinic agonists: pharmacology and computer-assisted molecular modeling study. 1989

C E Spivak, and J S Yadav, and W C Shang, and M Hermsmeier, and T M Gund
Addiction Research Center, National Institute on Drug Abuse, Baltimore, Maryland 21224.

To investigate how the substitution of NH2 for CH3 affects the activity of three, potent, semirigid nicotinic agonists, carbamyl analogues were synthesized. The carbamyl agonists were 1-methyl-4-carbamyl-1,2,3,6-tetrahydropyridine methiodide (1), 1-methyl-4-carbamylpiperidine methiodide (2), and 1-methyl-4-carbamylpiperazine methiodide (3). Their potencies (reciprocals of the equipotent molar ratios) at the frog neuromuscular junction with reference to carbamylcholine were 0.77, 0.052, and 0.15, respectively. The acetyl analogues were more potent by factors of 65, 175, and 17, respectively. Explanations for this variable reduction in activity were sought by using computer-assisted molecular mechanics and calculations of electrostatic potential contours. Bioactive conformations of 1-3 were assigned on the basis of a well-supported pharmacophore and the ground-state conformation of the highly potent (50 times that of carbamylcholine) prototype, isoarecolone methiodide (4). Agonist 3 and its acetyl analogue superimposed closely in their ground-state, bioactive conformations, and the differences in their electrostatic potential contours were the least among the three pairs. Accordingly, their potencies differed the least. Agonists 1 and 2 both showed greater differences (with respect to their acetyl analogues) in their electrostatic potential contours and greater differences in potency. Agonist 2, in addition, could achieve the bioactive conformation only at the expense of 2.8 kcal mol-1, and, correspondingly, its activity relative to its acetyl analogue was lowest of all.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D010277 Parasympathomimetics Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. Parasympathomimetic Agents,Parasympathomimetic Drugs,Parasympathomimetic Effect,Parasympathomimetic Effects,Agents, Parasympathomimetic,Drugs, Parasympathomimetic,Effect, Parasympathomimetic,Effects, Parasympathomimetic
D011978 Receptors, Nicotinic One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for NICOTINE over MUSCARINE. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors. Nicotinic Acetylcholine Receptors,Nicotinic Receptors,Nicotinic Acetylcholine Receptor,Nicotinic Receptor,Acetylcholine Receptor, Nicotinic,Acetylcholine Receptors, Nicotinic,Receptor, Nicotinic,Receptor, Nicotinic Acetylcholine,Receptors, Nicotinic Acetylcholine
D003196 Computer Graphics The process of pictorial communication, between human and computers, in which the computer input and output have the form of charts, drawings, or other appropriate pictorial representation. Computer Graphic,Graphic, Computer,Graphics, Computer
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

C E Spivak, and J S Yadav, and W C Shang, and M Hermsmeier, and T M Gund
December 1993, Journal of clinical pharmacology,
C E Spivak, and J S Yadav, and W C Shang, and M Hermsmeier, and T M Gund
January 1998, Acta pharmaceutica Hungarica,
C E Spivak, and J S Yadav, and W C Shang, and M Hermsmeier, and T M Gund
November 2010, Bioorganic & medicinal chemistry,
C E Spivak, and J S Yadav, and W C Shang, and M Hermsmeier, and T M Gund
August 2006, European journal of medicinal chemistry,
C E Spivak, and J S Yadav, and W C Shang, and M Hermsmeier, and T M Gund
September 2008, Bioorganic & medicinal chemistry letters,
C E Spivak, and J S Yadav, and W C Shang, and M Hermsmeier, and T M Gund
January 2004, Bioorganic & medicinal chemistry,
C E Spivak, and J S Yadav, and W C Shang, and M Hermsmeier, and T M Gund
February 2019, Journal of medicinal chemistry,
C E Spivak, and J S Yadav, and W C Shang, and M Hermsmeier, and T M Gund
March 2003, Journal of medicinal chemistry,
C E Spivak, and J S Yadav, and W C Shang, and M Hermsmeier, and T M Gund
January 1993, ALTEX,
C E Spivak, and J S Yadav, and W C Shang, and M Hermsmeier, and T M Gund
May 2020, Journal of molecular graphics & modelling,
Copied contents to your clipboard!